Biotechnology company developing disease-modifying small-molecule therapeutics to prevent axonal degeneration in neurological diseases, including multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies
Biotechnology company developing disease-modifying small-molecule therapeutics to prevent axonal degeneration in neurological diseases, including multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies. Its approach targets SARM1, a driver of axon degeneration.